International union of pharmacology. LXIV. Estrogen receptors

Pharmacological Reviews

Volumn 58, Issue 4, 2006, Pages 773-781

  Dahlman Wright, Karin ^a   Cavailles, Vincent ^b   Fuqua, Suzanne A ^c   Jordan, V Craig ^d   Katzenellenbogen, John A ^e   Korach, Kenneth S ^f   Maggi, Adriana ^g   Muramatsu, Masami ^h   Parker, Malcolm G ⁱ   Gustafsson, Jan Åke ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSERM   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g UNIVERSITY OF MILAN   (Italy)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 HYDROXYPHENYL) 4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 2H 1 BENZOPYRAN 7 OL; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ARZOXIFENE; BAZEDOXIFENE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; FULVESTRANT; GENISTEIN; GESTAGEN; HEXESTROL; HISTONE DEACETYLASE INHIBITOR; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE METABOLISM; BREAST TUMOR; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BINDING; DRUG EXCRETION; DRUG MECHANISM; ENDOMETRIUM CANCER; GENETIC SCREENING; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; ISCHEMIA; MENOPAUSAL SYNDROME; MULTIPLE SCLEROSIS; MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; HUMANS; MUTATION; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33751542905     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.58.4.8     Document Type: Review

References (69)

1. Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, and Hernan MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62:1362-1365.
2. Bailey CJ and Ahmed-Sorour H (1980) Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia 19:475-481.
3. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, and Nilsson S (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54:105-112.
4. Bhavnani BR (2003) Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 85:473-482.
5. Brandi ML, Becherini L, Gennari L, Racchi M, Bianchetti A, Nacmias B, Sorbi S, Mecocci P, Senin U, and Govoni S (1999) Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. Biochem Biophys Res Commun 265:335-338.
6. Brinton RD (2004) Impact of estrogen therapy on Alzheimer's disease: a fork in the road? CNS Drugs 18:405-422.
7. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J-A, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
8. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC Jr, Albert LM, Leathurby Y, Harris HA, Bhat RA, et al. (2005) Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci USA 102:2543-2548.
9. Chu S and Fuller PJ (1997) Identification of a splice variant of the rat estrogen receptor beta gene. Mol Cell Endocrinol 132:195-199.
10. Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, and Millikan RC (2005) The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 7:R871-R880.
11. Couse JF and Korach KS (2004) Estrogen receptor-alpha mediates the detrimental effects of neonatal diethylstilbestrol (DES) exposure in the murine reproductive tract. Toxicology 205:55-63.
12. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, and Fuqua SA (2004) Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res 64:9199-9208.
13. Cuzzocrea S, Santagati S, Sautebin L, Mazzon E, Calabro G, Serraino I, Caputi AP, and Maggi A (2000) 17beta-estradiol antiinflammatory activity in carrageenan-induced pleurisy. Endocrinology 141:1455-1463.
14. del Senno L, Aguiari GL, and Piva R (1992) Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene. Hum Mol Genet 1:354.
15. Delaunay F, Pettersson K, Tujague M, and Gustafsson JA (2000) Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58:584-590.
16. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, and Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843-854.
17. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, and Gannon F (2000) Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO (Eur Mol Biol Organ) J 19:4688-4700.
18. Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, and Moore JT (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59:5425-5428.
19. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, et al. (2000) A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60:4026-4029.
20. Garinis GA, Patrinos GP, Spanakis NE, and Menounos PG (2002) DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111:115-127.
21. Gotteland M, Desauty G, Delarue JC, Liu L, and May E (1995) Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Mol Cell Endocrinol 112:1-13.
22. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, and Chambon P (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (Lond) 320:134-139.
23. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, and Shine J (1986) Sequence and expression of human estrogen receptor complementary DNA. Science (Wash DC) 231:1150-1154.
24. Harman SM, Naftolin F, Brinton EA, and Judelson DR (2005) Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann NY Acad Sci 1052:43-56.
25. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, et al. (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854.
26. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, and Bleecker ER (2002) Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 346:967-974.
27. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M, and Gustafsson JA (2004) Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 101:9375-9380.
28. Iwao K, Miyoshi Y, Egawa C, Ikeda N, and Noguchi S (2000) Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer 88:733-736.
29. Jensen EV and Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980-1989.
30. Jordan VC, Phelps E, and Lindgren JU (1987) Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35.
31. Khan NS and Malhotra S (2003) Effect of hormone replacement therapy on cardiovascular disease: current opinion. Expert Opin Pharmacother 4:667-674.
32. Klinge CM (2000) Estrogen receptor interaction with co-activators and co-repressors. Steroids 65:227-251.
33. Kos M, Reid G, Denger S, and Gannon F (2001) Minireview: genomic organization of the human ERalpha gene promoter region. Mol Endocrinol 15:2057-2063.
34. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, and Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930.
35. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, and Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252-4263.
36. Lazennec G, Bresson D, Lucas A, Chauveau C, and Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120-4130.
37. Leygue E, Dotzlaw H, Lu B, Glor C, Watson PH, and Murphy LC (1998) Estrogen receptor beta: mine is longer than yours? J Clin Endocrinol Metab 83:3754-3755.
38. Li LC, Yeh CC, Nojima D, and Dahiya R (2000) Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 275:682-689.
39. Liu HB, Loo KK, Palaszynski K, Ashouri J, Lubahn DB, and Voskuhl RR (2003) Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease. J Immunol 171:6936-69340.
40. Lovejoy JC (2003) The menopause and obesity. Prim Care 30:317-325.
41. Maruyama K, Endoh H, Sasaki-Iwaoka H, Kanou H, Shimaya E, Hashimoto S, Kato S, and Kawashima H (1998) A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regular of estrogen action. Biochem Biophys Res Commun 246:142-147.
42. Mendelsohn ME and Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811.
43. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, and Katzenellenbogen JA (1999) Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem 42:2456-2468.
44. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, and Katzenellenbogen JA (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44:4230-4251.
45. Nilsson M, Naessen S, Dahlman I, Linden Hirschberg A, Gustafsson JA, and Dahlman-Wright K (2004) Association of estrogen receptor beta gene polymorphisms with bulimic disease in women. Mol Psychiatry 9:28-34.
46. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, and Inoue S (2000a) Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet 45:327-330.
47. Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M, Ouchi Y, and Inoue S (2000b) Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 269:537-541.
48. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, and Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26:3505-3512.
49. Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, and Goldhirsch A (2004) Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15:1749-1759.
50. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, and Mendelsohn ME (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092.
51. Poola I and Speirs V (2001) Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol 78:459-469.
52. Rosenkranz K, Hinney A, Ziegler A, Hermann H, Fichter M, Mayer H, Siegfried W, Young JK, Remschmidt H, and Hebebrand J (1998) Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J Clin Endocrinol Metab 83:4524-4527.
53. Safe S (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62:231-252.
54. Shang Y and Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science (Wash DC) 295:2465-2468.
55. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, and Greene GL (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364.
56. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, and Baron R (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30:18-25.
57. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, and Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061.
58. Soldan SS, Alvarez Retuerto AI, Sicotte NL, and Voskuhl RR (2003) Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 171:6267-6274.
59. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, and Katzenellenbogen JA (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43:4934-4947.
60. Taylor RA, Cowin P, Couse JF, Korach KS, and Risbridger GP (2006) 17beta-estradiol induces apoptosis in the developing rodent prostate independently of ERalpha or ERbeta. Endocrinology 147:191-200.
61. Tokunaga E, Kimura Y, and Maehara Y (2004) No hypersensitive estrogen receptor-alpha mutation (K303R) in Japanese breast carcinomas. Breast Cancer Res Treat 84:289-292.
62. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, and McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30.
63. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, et al. (2006) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2784-2786.
64. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, et al. (2001) Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276:18375-18383.
65. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, and Gustafsson JA (2003) Update on estrogen signaling. FEBS Lett 546:17-24.
66. Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A, Baygani SK, Anderson PW, and Moscarelli E (2002) Baseline characteristics of participants in the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol 90:1204-1210.
67. Xu L, Pan-Hammarstrom Q, Forsti A, Hemminki K, Hammarstrom L, Labuda D, Gustafsson JA, and Dahlman-Wright K (2003) Human estrogen receptor beta 548 is not a common variant in three distinct populations. Endocrinology 144:3541-3546.
68. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, and Dahlman-Wright K (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22:7600-7606.
69. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, et al. (2002) Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (Wash DC) 295:505-508.